Valo Health to Participate in June Conferences and Events

CEO & Founder David Berry and Chief Artificial Intelligence Officer, Brandon Allgood to present in upcoming events

BOSTON, June 2, 2022 /​PRNewswire/​— Valo Health, Inc (“Valo”), the tech­nol­o­gy com­pa­ny focused on trans­form­ing the drug dis­cov­ery and devel­op­ment process using human-cen­tric data and arti­fi­cial intel­li­gence, today announced its par­tic­i­pa­tion in the fol­low­ing upcom­ing investor con­fer­ences and events:

David Berry, Valo Health CEO and founder:

  • New York Stock Exchange Health & Tech­nol­o­gy Investor Access vir­tu­al event — June 82022
  • Jef­feries Health­care Con­fer­ence, New York, NY — June 102022
  • Mor­gan Stan­ley, Putting the Tech in Biotech: Explor­ing the World of Tech-Enabled Drug Devel­op­ment, New York, NY – June 282022
  • The Uni­ver­si­ty of Chica­go Pol­sky Cen­ter, Keynote Speak­er, Com­pass Demo Day – June 292022

Bran­don All­go­od, Chief Arti­fi­cial Intel­li­gence Officer:

  • Egnyte annu­al Life Sci­ences Vir­tu­al Sum­mit regard­ing the use of AI in drug dis­cov­ery and clin­i­cal tri­als — June 152022

About Valo Health
Valo Health, Inc (“Valo”) is a tech­nol­o­gy com­pa­ny built to trans­form the drug dis­cov­ery and devel­op­ment process using human-cen­tric data and arti­fi­cial intel­li­gence dri­ven com­pu­ta­tion. As a dig­i­tal­ly native com­pa­ny, Valo aims to ful­ly inte­grate human-cen­tric data across the entire drug devel­op­ment life cycle into a sin­gle uni­fied archi­tec­ture, there­by accel­er­at­ing the dis­cov­ery and devel­op­ment of life-chang­ing drugs while simul­ta­ne­ous­ly reduc­ing costs, time, and fail­ure rates. The com­pa­ny’s Opal Com­pu­ta­tion­al Plat­form is an inte­grat­ed set of capa­bil­i­ties designed to trans­form data into valu­able insights that may accel­er­ate dis­cov­er­ies and enable Valo to advance a robust pipeline of pro­grams across car­dio­vas­cu­lar meta­bol­ic renal, oncol­o­gy, and neu­rode­gen­er­a­tive dis­ease. Found­ed by Flag­ship Pio­neer­ing and head­quar­tered in Boston, MA, Valo also has offices in Lex­ing­ton, MA, New York, NY, Bran­ford, CT, and San Fran­cis­co, CA. To learn more, vis­it www​.val​o​health​.com.

Investors: Graeme Bell, Chief Finan­cial Offi­cer